Istiratumab (M-6495) 是靶向 IGF-1R 和 ErbB3 的双特异性单克隆抗体。Istiratumab 通过蛋白酶体途径诱导 IGF-1R 和 ErbB3 受体降解。Istiratumab 可用于癌症研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-HER3 & IGF-1R Reference Antibody (Istiratumab) is 199.64 kDa.

Anti-HER3 & IGF-1R Reference Antibody (Istiratumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-HER3 & IGF-1R Reference Antibody (Istiratumab) is 95.55 %, determined by SEC-HPLC.

Istiratumab bound to 4-1BB protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Istiratumab bound to Human IGF-1R-His, and the EC50 was 0.022 nM.

Istiratumab bound to HER3 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Istiratumab bound to Human HER3-His, and the EC50 was 0.046 nM.

Istiratumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Istiratumab bound to 0920-13 Hu-HER3-FL-HEK293-A4 cells, and the EC50 was 1.257 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.